Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARMA: UD-NK Cells for Relapsed/Refractory AML
NCT05503134Phase 2Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Feb 2022
- Primary completion
- Feb 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Universal Donor Natural Killer Cells in acute myeloid leukemia (AML), sponsored by Nationwide Children's Hospital. Started Feb 2022; status: recruiting.
02
Drugs
Universal Donor Natural Killer Cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05503134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503134.